Medistim

Regulatory Filings • Aug 9, 2017

Medistim has received clearance for sale of MiraQ in China

Medistim has received clearance for sale of MiraQ in China

(Oslo, August 9th, 2017) Medistim ASA (OSE: MEDI), a niche market

leader within ultrasound technology with headquarter in Norway, that

develops and commercializes medical equipment for use within

cardiac, vascular and transplant surgery, announces that they have

received clearance from the China Food and Drug Administration

(CFDA) for sale of its product MiraQ.

MiraQ represent Medistim's most advanced system for ultrasonic

surgical guidance and quality assessment used intraoperatively

during coronary artery bypass grafting (CABG) as well as vascular

and transplant surgery. The system combines state-of-art transit

time blood flow measurement (TTFM) with a high frequency ultrasound

imaging modality. By adding ultrasound imaging to blood flow

measurements, it will become easier for the surgeon to plan,

optimize and assess quality of the surgical procedure. MiraQ is a

unique tool that can contribute to improved surgical precision and

quality, which may ultimately provide better outcomes for the

patients.

Medistim has already launched MiraQ in the USA, Europe and other

markets accepting the CE certificate, and is now positioned to sell

the product in all its major markets except Japan, where an

application is in process.

Globally, about 700 000 coronary artery bypass graft (CABG)

procedures and 600 000 vascular procedures are being performed every

year. China represents a significant market opportunity for

Medistim with about 50 000 CABG procedures performed per year and a

projected annual growth rate of 5 to 10 %. Today, Medistim covers

>30 % of these procedures with its traditional flow measurement

system VeriQ. "Medistim is well positioned for further growth in

China, with a number of systems placed with the largest cardiac

centers and supported by leading Chinese surgeons", says Kari E.

Krogstad, President and CEO in Medistim ASA and continues: "Finally,

we can offer our premium product to the Chinese market. There is

already a growing interest for the combination of ultrasound imaging

and TTFM measurements amongst surgeons in China, and the future

outlook is good."

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: thomas.jakobsen@medistim.com

About Medistim

Medistim was established in 1984, and has a track record of

profitable growth over the past >10 years. The company is a pioneer

within its segment, and continues to invest in new product

development. Medistim has wholly owned subsidiaries with sales

organizations in the US, Germany, Denmark, UK, Spain and Norway, in

addition to the about 50 distributors in Europe, Asia, Middle East,

Africa and South America. For more information, visit the Medistim

home page: www.Medistim.com

This information is disclosed under Norwegian law

(Verdipapirhandelloven §5-12).